Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Withdrawn 1Completed 1Available 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 4Melanoma 2Sarcoma, Clear Cell 1Sarcoma 1Nevus, Blue 1Neoplasm Metastasis 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 54Nivolumab 50Ipilimumab 28Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Biopsy 8aldesleukin 7Interleukin-2 7atezolizumab 6Immunotherapy 6Blood Specimen Collection 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4fludarabine phosphate 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Melanoma × tebentafusp × Clear all
NCT07057596 2026-03-06

NEO-TB

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting
19 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡